Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress Disorders, Post-Traumatic | 44 | 2023 | 1506 | 4.150 |
Why?
|
| Psychotic Disorders | 11 | 2018 | 157 | 2.700 |
Why?
|
| Veterans | 31 | 2023 | 904 | 1.720 |
Why?
|
| Antipsychotic Agents | 10 | 2019 | 247 | 1.690 |
Why?
|
| Combat Disorders | 16 | 2018 | 102 | 1.590 |
Why?
|
| Antidepressive Agents | 7 | 2022 | 216 | 1.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2022 | 189 | 0.810 |
Why?
|
| Double-Blind Method | 12 | 2023 | 1738 | 0.680 |
Why?
|
| Piperazines | 2 | 2019 | 206 | 0.660 |
Why?
|
| Implosive Therapy | 3 | 2020 | 171 | 0.640 |
Why?
|
| Thiazoles | 1 | 2019 | 95 | 0.640 |
Why?
|
| Prodromal Symptoms | 1 | 2018 | 5 | 0.630 |
Why?
|
| Psychiatric Status Rating Scales | 15 | 2019 | 782 | 0.620 |
Why?
|
| Schizophrenia | 5 | 2012 | 206 | 0.620 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2018 | 15 | 0.610 |
Why?
|
| Yohimbine | 1 | 2018 | 41 | 0.600 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 72 | 0.590 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.550 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2016 | 257 | 0.530 |
Why?
|
| Humans | 72 | 2023 | 68618 | 0.520 |
Why?
|
| Male | 54 | 2022 | 37321 | 0.500 |
Why?
|
| Criminal Law | 1 | 2014 | 30 | 0.460 |
Why?
|
| Anti-Anxiety Agents | 3 | 2001 | 107 | 0.450 |
Why?
|
| Adult | 36 | 2022 | 21403 | 0.440 |
Why?
|
| Middle Aged | 38 | 2022 | 21147 | 0.440 |
Why?
|
| Mobile Applications | 1 | 2015 | 138 | 0.440 |
Why?
|
| Dibenzothiazepines | 3 | 2005 | 15 | 0.420 |
Why?
|
| Treatment Outcome | 15 | 2023 | 7029 | 0.420 |
Why?
|
| Quetiapine Fumarate | 5 | 2018 | 20 | 0.400 |
Why?
|
| Tobacco Use Disorder | 1 | 2015 | 432 | 0.360 |
Why?
|
| School Admission Criteria | 2 | 2020 | 36 | 0.340 |
Why?
|
| Valproic Acid | 1 | 2009 | 93 | 0.320 |
Why?
|
| Students, Nursing | 2 | 2020 | 101 | 0.310 |
Why?
|
| Comorbidity | 8 | 2018 | 1426 | 0.300 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 951 | 0.300 |
Why?
|
| Military Personnel | 4 | 2017 | 221 | 0.290 |
Why?
|
| Fear | 2 | 2018 | 239 | 0.290 |
Why?
|
| Depressive Disorder | 5 | 1999 | 621 | 0.280 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2014 | 24 | 0.280 |
Why?
|
| Buspirone | 2 | 1997 | 36 | 0.270 |
Why?
|
| Female | 24 | 2022 | 38074 | 0.270 |
Why?
|
| Smoking Cessation | 1 | 2015 | 1034 | 0.270 |
Why?
|
| Young Adult | 7 | 2020 | 5717 | 0.270 |
Why?
|
| Depressive Disorder, Major | 2 | 2022 | 439 | 0.270 |
Why?
|
| Drug Resistance | 2 | 2004 | 223 | 0.270 |
Why?
|
| Psychotherapy | 2 | 2005 | 253 | 0.250 |
Why?
|
| Warfare | 3 | 2005 | 58 | 0.250 |
Why?
|
| Personality Inventory | 3 | 2004 | 197 | 0.250 |
Why?
|
| Norepinephrine | 2 | 2014 | 276 | 0.250 |
Why?
|
| Cross-Over Studies | 2 | 2022 | 260 | 0.230 |
Why?
|
| MMPI | 4 | 2004 | 40 | 0.220 |
Why?
|
| Delusions | 2 | 2000 | 20 | 0.220 |
Why?
|
| Hallucinations | 2 | 2000 | 19 | 0.220 |
Why?
|
| Hyperprolactinemia | 1 | 2002 | 3 | 0.210 |
Why?
|
| Risperidone | 1 | 2003 | 48 | 0.210 |
Why?
|
| Alcoholism | 3 | 2023 | 1109 | 0.210 |
Why?
|
| Pharmacogenomic Testing | 1 | 2022 | 7 | 0.210 |
Why?
|
| Dopamine | 2 | 1996 | 474 | 0.210 |
Why?
|
| Sertraline | 2 | 2020 | 62 | 0.210 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2022 | 14 | 0.210 |
Why?
|
| Propylamines | 1 | 2022 | 22 | 0.200 |
Why?
|
| Inappropriate Prescribing | 1 | 2022 | 27 | 0.200 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2022 | 20 | 0.200 |
Why?
|
| Gyrus Cinguli | 2 | 2002 | 113 | 0.200 |
Why?
|
| Drug Interactions | 1 | 2022 | 289 | 0.200 |
Why?
|
| Rivastigmine | 1 | 2021 | 6 | 0.190 |
Why?
|
| Acetates | 1 | 2001 | 74 | 0.190 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2001 | 60 | 0.190 |
Why?
|
| Prolactin | 2 | 2002 | 61 | 0.190 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 58 | 0.190 |
Why?
|
| Amines | 1 | 2001 | 98 | 0.180 |
Why?
|
| Polymorphism, Genetic | 3 | 2021 | 301 | 0.180 |
Why?
|
| Nursing Education Research | 1 | 2020 | 35 | 0.180 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2009 | 88 | 0.180 |
Why?
|
| Schizophrenic Psychology | 1 | 2000 | 53 | 0.180 |
Why?
|
| Substance-Related Disorders | 4 | 2016 | 1242 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 649 | 0.170 |
Why?
|
| Wakefulness | 1 | 2020 | 75 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2022 | 652 | 0.170 |
Why?
|
| Pilot Projects | 3 | 2019 | 1342 | 0.170 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2001 | 208 | 0.170 |
Why?
|
| Education, Nursing, Baccalaureate | 1 | 2020 | 50 | 0.170 |
Why?
|
| Student Dropouts | 1 | 2019 | 7 | 0.170 |
Why?
|
| Brain | 3 | 2004 | 2176 | 0.170 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2021 | 105 | 0.170 |
Why?
|
| Risk Factors | 4 | 2019 | 5731 | 0.170 |
Why?
|
| Schools, Nursing | 1 | 2019 | 19 | 0.170 |
Why?
|
| Paroxetine | 1 | 2019 | 28 | 0.160 |
Why?
|
| Child Abuse, Sexual | 1 | 2000 | 150 | 0.160 |
Why?
|
| Chronic Disease | 4 | 2009 | 1330 | 0.160 |
Why?
|
| Behavioral Symptoms | 1 | 1999 | 32 | 0.160 |
Why?
|
| Tay-Sachs Disease | 1 | 1998 | 1 | 0.160 |
Why?
|
| Cyclohexanols | 1 | 1998 | 12 | 0.160 |
Why?
|
| Hydrocortisone | 1 | 2020 | 291 | 0.160 |
Why?
|
| Conditioning, Classical | 1 | 1999 | 57 | 0.160 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 1998 | 54 | 0.160 |
Why?
|
| Retrospective Studies | 4 | 2018 | 7277 | 0.160 |
Why?
|
| Educational Measurement | 1 | 2020 | 254 | 0.160 |
Why?
|
| Citalopram | 2 | 2009 | 30 | 0.150 |
Why?
|
| Cognition | 1 | 2002 | 513 | 0.150 |
Why?
|
| Adolescent | 4 | 2018 | 8912 | 0.150 |
Why?
|
| Psychological Trauma | 1 | 2018 | 32 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 176 | 0.150 |
Why?
|
| Pregnanolone | 1 | 2017 | 6 | 0.150 |
Why?
|
| Severity of Illness Index | 8 | 2011 | 1851 | 0.150 |
Why?
|
| Psychomotor Disorders | 1 | 1996 | 4 | 0.140 |
Why?
|
| Neurosyphilis | 1 | 2016 | 7 | 0.140 |
Why?
|
| Anxiety Disorders | 2 | 2015 | 426 | 0.140 |
Why?
|
| Huntington Disease | 1 | 1996 | 15 | 0.140 |
Why?
|
| Vietnam | 5 | 2005 | 36 | 0.140 |
Why?
|
| Clozapine | 1 | 1996 | 46 | 0.140 |
Why?
|
| Patient Care Team | 2 | 1999 | 311 | 0.130 |
Why?
|
| Curriculum | 1 | 2020 | 575 | 0.130 |
Why?
|
| Hyperthermia, Induced | 1 | 2016 | 53 | 0.130 |
Why?
|
| Cholecystokinin | 1 | 2015 | 29 | 0.130 |
Why?
|
| Diagnosis, Differential | 5 | 2000 | 1140 | 0.130 |
Why?
|
| Defibrillators, Implantable | 1 | 1999 | 329 | 0.130 |
Why?
|
| Neuropsychological Tests | 4 | 2020 | 517 | 0.120 |
Why?
|
| Thiones | 1 | 2014 | 16 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 786 | 0.120 |
Why?
|
| Criminal Behavior | 1 | 2014 | 1 | 0.120 |
Why?
|
| Clonazepam | 1 | 1994 | 6 | 0.120 |
Why?
|
| Sick Role | 1 | 1994 | 40 | 0.120 |
Why?
|
| Erectile Dysfunction | 1 | 1994 | 22 | 0.120 |
Why?
|
| GABA Modulators | 1 | 1994 | 26 | 0.120 |
Why?
|
| Domestic Violence | 1 | 2014 | 36 | 0.110 |
Why?
|
| Genotype | 4 | 2021 | 786 | 0.110 |
Why?
|
| Imidazoles | 1 | 2014 | 175 | 0.110 |
Why?
|
| Quality of Life | 1 | 2022 | 1515 | 0.110 |
Why?
|
| Acetylcysteine | 1 | 2016 | 296 | 0.110 |
Why?
|
| Cues | 1 | 2017 | 654 | 0.110 |
Why?
|
| Iraq War, 2003-2011 | 2 | 2010 | 85 | 0.100 |
Why?
|
| Sleep Wake Disorders | 2 | 2005 | 94 | 0.100 |
Why?
|
| Porphyrias | 1 | 1992 | 3 | 0.100 |
Why?
|
| beta-Endorphin | 1 | 1992 | 15 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2022 | 307 | 0.100 |
Why?
|
| Neurocognitive Disorders | 1 | 1992 | 23 | 0.100 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 51 | 0.100 |
Why?
|
| Electroconvulsive Therapy | 1 | 1996 | 402 | 0.100 |
Why?
|
| Time Factors | 2 | 2016 | 4655 | 0.100 |
Why?
|
| Remission Induction | 2 | 2022 | 111 | 0.100 |
Why?
|
| Child | 2 | 2018 | 6405 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 170 | 0.090 |
Why?
|
| Exercise Test | 1 | 1992 | 242 | 0.090 |
Why?
|
| Limbic System | 2 | 2002 | 106 | 0.090 |
Why?
|
| Aged | 9 | 2005 | 14862 | 0.090 |
Why?
|
| United States | 7 | 2022 | 7367 | 0.080 |
Why?
|
| Quinolones | 1 | 2009 | 60 | 0.080 |
Why?
|
| Cocaine | 1 | 1993 | 555 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 1745 | 0.080 |
Why?
|
| Survivors | 2 | 2000 | 256 | 0.070 |
Why?
|
| Life Change Events | 3 | 2007 | 223 | 0.070 |
Why?
|
| Cholinergic Antagonists | 1 | 2006 | 17 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 848 | 0.070 |
Why?
|
| Reaction Time | 2 | 2017 | 170 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1753 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2006 | 83 | 0.070 |
Why?
|
| Expert Testimony | 1 | 2005 | 47 | 0.060 |
Why?
|
| Urea | 1 | 2004 | 51 | 0.060 |
Why?
|
| Veterans Disability Claims | 1 | 2003 | 11 | 0.060 |
Why?
|
| Speech | 1 | 2004 | 118 | 0.060 |
Why?
|
| Phobic Disorders | 1 | 2004 | 227 | 0.060 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2023 | 20 | 0.050 |
Why?
|
| Doxazosin | 1 | 2023 | 20 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 2800 | 0.050 |
Why?
|
| Prisoners | 1 | 2003 | 50 | 0.050 |
Why?
|
| Alleles | 2 | 2015 | 386 | 0.050 |
Why?
|
| Placebos | 1 | 2003 | 195 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2003 | 219 | 0.050 |
Why?
|
| Thalamic Nuclei | 1 | 2002 | 9 | 0.050 |
Why?
|
| Maternal Behavior | 1 | 2002 | 29 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2022 | 47 | 0.050 |
Why?
|
| Income | 1 | 2003 | 167 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2003 | 94 | 0.050 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2002 | 109 | 0.050 |
Why?
|
| Employment | 1 | 2003 | 154 | 0.050 |
Why?
|
| Mental Health Services | 1 | 2004 | 199 | 0.050 |
Why?
|
| Anxiety | 1 | 2004 | 422 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 109 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2004 | 383 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2021 | 21 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1553 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2358 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 216 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2021 | 82 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 201 | 0.040 |
Why?
|
| Nerve Net | 1 | 2002 | 181 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 150 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2020 | 138 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 123 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2005 | 703 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2005 | 659 | 0.040 |
Why?
|
| Procaine | 1 | 1999 | 9 | 0.040 |
Why?
|
| Receptors, Adrenergic | 1 | 1999 | 68 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2003 | 445 | 0.040 |
Why?
|
| Sensory Thresholds | 1 | 1999 | 50 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 166 | 0.040 |
Why?
|
| Lithium Carbonate | 1 | 1998 | 31 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1998 | 45 | 0.040 |
Why?
|
| Desipramine | 1 | 1998 | 47 | 0.040 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 1998 | 42 | 0.040 |
Why?
|
| Telemedicine | 1 | 2007 | 700 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2000 | 340 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 307 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 1999 | 83 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2000 | 1040 | 0.040 |
Why?
|
| Models, Neurological | 1 | 1999 | 136 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 546 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2017 | 38 | 0.040 |
Why?
|
| Arousal | 2 | 2002 | 168 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2005 | 2279 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 2004 | 824 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2000 | 342 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2004 | 2223 | 0.040 |
Why?
|
| Task Performance and Analysis | 1 | 2017 | 150 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 106 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2016 | 151 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1997 | 260 | 0.030 |
Why?
|
| Chlorpromazine | 1 | 1996 | 7 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2000 | 468 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 127 | 0.030 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1995 | 30 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 248 | 0.030 |
Why?
|
| Age Factors | 1 | 2000 | 1864 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1420 | 0.030 |
Why?
|
| Piperidines | 1 | 1995 | 123 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2009 | 3705 | 0.030 |
Why?
|
| Panic Disorder | 1 | 2015 | 121 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Craving | 1 | 2016 | 200 | 0.030 |
Why?
|
| Dreams | 1 | 1994 | 12 | 0.030 |
Why?
|
| Alprazolam | 1 | 1994 | 35 | 0.030 |
Why?
|
| Diazepam | 1 | 1994 | 23 | 0.030 |
Why?
|
| Knee Injuries | 1 | 1994 | 31 | 0.030 |
Why?
|
| Lorazepam | 1 | 1994 | 54 | 0.030 |
Why?
|
| Spinal Fractures | 1 | 1994 | 43 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3259 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 615 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 1994 | 86 | 0.030 |
Why?
|
| Mental Recall | 1 | 1993 | 72 | 0.030 |
Why?
|
| Recurrence | 1 | 1994 | 948 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 2689 | 0.020 |
Why?
|
| Brain Mapping | 2 | 2004 | 532 | 0.020 |
Why?
|
| Afghan Campaign 2001- | 1 | 2010 | 78 | 0.020 |
Why?
|
| Acute Disease | 1 | 1992 | 658 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 521 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 335 | 0.020 |
Why?
|
| Aripiprazole | 1 | 2009 | 43 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 737 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1994 | 807 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2006 | 49 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 567 | 0.020 |
Why?
|
| Psychiatry | 1 | 2006 | 112 | 0.020 |
Why?
|
| Peroxides | 1 | 2004 | 23 | 0.020 |
Why?
|
| Heart Failure | 1 | 1994 | 1180 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2004 | 304 | 0.010 |
Why?
|
| Utilization Review | 1 | 2004 | 48 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 438 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2004 | 147 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 306 | 0.010 |
Why?
|
| Communication | 1 | 2005 | 329 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2004 | 186 | 0.010 |
Why?
|
| Preoptic Area | 1 | 2002 | 19 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 2002 | 65 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2004 | 298 | 0.010 |
Why?
|
| Data Collection | 1 | 2003 | 420 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 689 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 2002 | 156 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 1619 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 378 | 0.010 |
Why?
|
| Malingering | 1 | 2000 | 36 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2000 | 96 | 0.010 |
Why?
|
| South Carolina | 1 | 2003 | 2752 | 0.010 |
Why?
|
| Prefrontal Cortex | 1 | 2002 | 640 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 2455 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 2891 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 4848 | 0.010 |
Why?
|